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Background: Investigation on incidence and mortality of anaerobic bacteremia (AB) is clinically relevant in spite of its infre-
quent occurrence and not often explored, which report varies according to period and institutions. Therefore, it is necessary to 
analyze the incidence and risk factors related to mortality and assess clinical outcomes of AB in current aspect. 
Materials and Methods: Characteristics of AB patients and anaerobic bacteria from blood culture at a university hospital in 
2012 were reviewed retrospectively. The correlation between risk factors and 28-day patient mortality was analyzed.
Results: A total of 70 non-duplicated anaerobic bacteria were isolated from blood of 70 bacteremia patients in 2012. The histo-
ry of cardiovascular disease as host’s risk factor was statistically significant (P = 0.0344) in univariate and multivariate analysis. 
Although the inappropriate therapy was not statistically significant in univariate and multivariate analysis, the survival rate of 
bacteremia was significantly worse in patients who had inappropriate therapy compared with those underwent appropriate 
therapy (hazard ratio, 5.4; 95% confidence interval, 1.7–16.9; P = 0.004). The most frequently isolated organism was Bacteroi-
des fragilis (32 isolates, 46%), followed by Bacteroides thetaiotaomicron (10, 14 %), and non-perfringens Clostridium (7, 10%). 
Conclusion: The incidence of AB in 2012 was 2.3% (number of AB patients per 100 positive blood culture patients) and the mor-
tality rate in patients with clinically significant AB was 21.4%. In addition, AB was frequently noted in patients having malignancy 
and the survival rate of AB was significantly worse in patients who received inappropriate therapy compared with those underwent 
appropriate therapy.
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Introduction
Anaerobic bacteremia (AB) is occasionally encountered in 
0.5-11.8% of all positive blood cultures [1, 2] depending on the 
institution. In spite of its infrequent occurrence, the fatal rate 
remains high from 25% to 44% [3, 4]. Due to such significant 
mortality, characterizing the risk factors associated with mor-
tality in patients with AB was previously attempted from the 
1970s. Generally, increasing age, polymicrobial infection, and 
underlying diseases were considered as factors contributing 
the mortality [5]. The significance of inappropriate antimicro-
bial treatment in mortality of AB patients was discussed in 
number of studies [6, 7], however, the association was not 
conclusive. Given the changes in antimicrobial therapy, clini-
cal characteristic of patients, and antimicrobial susceptibili-
ties, it is difficult to apply former studies to current circum-
stances. Moreover, to our knowledge, there have been limited 
studies defining factors associated with mortality of AB and 
whether the appropriate therapy contributed the survival of 
AB patients, based on bacterial susceptibilities. To these lim-
itations, the aims of the present study were to determine the 
clinical significance of anaerobes isolated from blood and as-
sess the risk factors related to mortality of patients with AB at 
a tertiary-care hospital in Korea. 
Materials and Methods
1. Patients
Seventy patients who experienced clinically relevant bacte-
remia between January and December of 2012 and hospital-
ized at Severance Hospital (a 2,000-bed university tertiary re-
ferral hospital in Seoul, Korea) were analyzed retrospectively 
by reviewing laboratory records and electronic medical re-
cords.
 
2. Microbiology
Blood cultures were obtained by general venipuncture 
guidelines to draw no less than 10 ml of blood when possible. 
Blood was injected to BacT/ALERT FA and  BacT/ALERT 
FN (bioMérieux, Marcy-l'Etoile, France) bottles. The positive 
blood cultures were inoculated on Brucella agar and phenyl-
ethyl alcohol blood agar, and then incubated in an anaero-
bic chamber (Forma Scientific, Marietta, OH, USA) at 35°C for 
48 hours. All isolates were identified by either conventional 
methods [8], the Vitek Anaerobe and Corynebacterium (ANC) 
identi f icat ion  card (bioMér ieux) ,  or  the VITEK MS 
(bioMérieux) matrix-assisted laser desorption ionisation-time 
of flight mass spectrometry (MALDI-TOF MS) system. An epi-
sode with positive culture of Propionibacterium acnes was ex-
cluded, which was considered as a common skin commensal. 
The antimicrobial susceptibility testing was performed for 44 
isolates of the Bacteroides fragilis group following the CLSI 
agar dilution method [9]. 
3. Definitions
Bacteremia was considered clinically relevant when a pa-
tient had one or more positive blood cultures for anaerobes 
and met one of the following SIRS (Systemic inflammatory re-
sponse syndrome) critera for documented or suspected infec-
tion: leukocyte count greater than 12,000/mm3 or less than 
4,000/mm3, body temperature higher than 38.3°C or lower 
than 36°C, pulse rate faster than 90/min, elevated C-reactive 
protein (CRP), hypotension or clinical evidence consistent 
with infection such as symptoms and signs of organ dysfunc-
tion [10]. 
The presence of an underlying disease was based on the de-
scription made by the physician. A patient was said to have 
cardiovascular disease when one or more of the following 
terms was used: chronic heart disase, coronary artery disease, 
hypertension, or cerebrovascular disease. 
The source of the infection was assessed using imaging stud-
ies, clinical symptoms and signs. Each episode was classified 
as community acquired (CA), hospital acquired (HA) and 
healthcare-associated (HCA) community onset infection by 
reviewing the patient's medical records according to guide-
lines suggested by Lenz et al. [11]. The infection was deemed 
to be HA if a positive culture was drawn after more than 48 
hours following admission or within 48 hours of discharge 
from hospital. A HCA was defined as first culture obtained 
less than 48 hours of admission and at least of: 1) visit to a 
hospital clinic or emergency department within the prior 5-30 
days before onset of bloodstream infection; 2) receipt of dialy-
sis; or 3) active cancer. CA are those with first positive culture 
obtained less than 48 hours of admission and not fulfilling cri-
teria for HCA. 
A delay in starting antimicrobials even after objective data 
confirmed an infection or the use of an antimicrobial agent to 
which the pathogen is resistant (by known susceptibility re-
sults) was considered inappopriate therapy [12, 13]. However, 
some treatments could not be classified in those patients dis-
charged without any prescriptions. The patients’ outcome was 
considered as either alive or dead within 28 days of the onset 
of bacteremia. 
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4. Statistics
Statistical analyses were performed using the SPSS software 
(version 23.0; SPSS Inc., Chicago, IL, USA). Means of non-nor-
mally distributed quantitative values were compared using 
the Mann-Whitney U test and correlation between nonpara-
metric characteristics and mortality was determined by Pear-
son Chi-square and Fisher's exact test. A two-tailed value of P 
< 0.05 was considered statistically signiﬁcant. Multivariate lo-
gistic regression analysis was used to determine associations 
between characteristics which were significant in univariate 
analysis with the value of P < 0.2 and mortality. Survival data 
were collected for 28 days following the onset of bacteremia, 
using Cox proportional-hazards regression model.
Results
1. Demographics and underlying diseases
A total of 70 non-duplicated subjects were included in the 
analysis, which incidence was 2.3%  (Number of AB patients 
per 100 positive blood culture patients) of 3,050 positive blood 
culture patients in 2012.  Thirty-eight (54.3%) patients were 
male. The median age of the patients was 61 (first quartile 50 
yrs; third quartile 69 yrs) years.
Thirty-five patients were > 60 years old, accounting for half 
of total patients. Fifty-six patients (70.0%) had malignancy as 
an underlying disease, 27 patients (38.6%) had histoty of sur-
gical procedure, 14 patients had liver disease (20.0%) and 11 
patients had cardiovascular disease (15.7%). The presence of 
cardiovascular disease was statistically significant (P = 0.049) 
Table 1. Host or microbial characteristics associated with 28-day mortality in 70 patients of anaerobic bacteremia
Characteristics/factors
No. (%) of patients P-value
All 
(No=70)
Alive 
(No =55)
Dead 
(No =15)
Univariatea Multivariateb
Age (median, interquartile range, years) 61 (50-69) 61 (48-69) 60 (50-77) 0.897
Age > 60 years 35 (50.0) 28 (50.9) 7 (46.7) 0.771
Male/Female (male, %) 38/32 (54.3) 33/22 (60.0) 5/10 (33.3) 0.066 0.050
Underlying diseases, n (%)
    Hematologic malignancy 6 (8.6) 4 (7.3) 2 (13.3) 1.000
    Non-hematologic malignancy 50 (71.4) 39 (70.9) 11 (73.3) 0.749
    Cardiovascular disease 11 (15.7) 6 (10.9) 5 (33.3) 0.049 0.045
    Previous surgery 27 (38.6) 21 (38.2) 6 (40.0) 0.898
    Diabetes mellitus 9 (12.9) 7 (12.7) 2 (13.3) 1.000
    Liver disease 14 (20.0) 10 (18.2) 4 (26.7) 0.480
Source of infection, n (%)
    Intra-abdominal 42 (60.0) 34 (61.8) 8 (53.3) 1.000
    Skin barrier penetration 5 (7.1) 5 (9.1) 0 (0.0) 0.577
    Respiratory 2 (2.9) 1 (1.8) 1 (6.7) 1.000
Origin of infection, n (%)
    Hospital-acquired infection 44 (62.9) 32 (58.2) 12 (80.0) 0.1210 1.000
    Community-acquired infection 2 (2.9) 2 (3.6) 0 (0.0) 1.000
    Healthcare-associated
       community onset infection
24 (34.3) 21 (38.2) 3 (20.0) 0.189 1.000
Polymicrobial infection 9 (12.9) 3 (5.5) 6 (40.0) 0.392
Bacteroides spp. infection 50 (71.4) 37 (67.3) 13 (86.7) 0.202
Inappropriate therapy 16 (22.9) 10 (18.2) 6 (40.0) 0.139 0.168
aThe Pearson χ2 test was used for categorical variables and the Mann-Whitney U test was used for continuous variables.
bThe multivariate logistic regression analysis was used to determine which variables were acting independently.
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in 28-day mortality, whereas other underlying diseases were 
not statistically significant in univariate analysis. The five sig-
nificant factors (P < 0.2) were examined using multivariate lo-
gistic regression analysis to determine which variables were 
acting independently. Cardiovascular disease was statistically 
significant in the multivariate analysis.
2. Source and onset of infection 
The most common sources of bacteremia among those were 
available to be determined were the intra-abdominal area (42 
patients, 60.0%), skin barrier penetration (5 patients, 7.1%) 
and the respiratory tract (2 patients, 2.9%). Forty-four patients 
(62.9%) were HA, 24 patients (34.3%) were HCA, while two 
patients (2.9%) were CA. Neither the source of infection nor 
where the infection was acquired was statistically related to 
28-day mortality (Table 1). 
3. Microbiology
The most frequently isolated organisms were B. fragilis (32 
isolates, 46%), Bacteroides thetaiotaomicron (10, 14%), and 
non-perfringens Clostridium (7, 10%) (Table 2). In 61 patients 
(87.1%), bacteremia was caused by a single organism. Nine 
patients (12.9%) had a polymicrobial infection, most com-
monly with coagulase-negative staphylococci, Escherichia 
coli, and Klebsiella pneumoniae (in order of frequency), how-
ever, the mortality was not significantly associated with mixed 
infections. Among the 70 patients, 50 patients had bacteremia 
due to Bacteroides spp., although the mortality was not statis-
tically significant. On an antibiogram (Table 3) for B. fragilis, 
the susceptibility rate to clindamycin, piperacillin and moxi-
floxacin were 50%, 75% and 78%, respectively, whereas the 
susceptibility rate to cefoxitin, piperacillin-tazobactam, imipe-
nem, meropenem, chloramphenicol, and metronidazole were 
91% to 100%. However, for other species of the B. fragilis 
group, the susceptibility rate to clindamycin, piperacillin, ce-
foxitin, and piperacillin-tazobactam, were 17%, 0%, 25%, and 
75%, respectively.
Table 2. Anaerobic organisms isolated from blood culture
Organisms No.(%) of patients
Bacteroides fragilis 32 (45.7)
Bacteroides thetaiotaomicron 10 (14.3)
Bacteroides ovatus 4 (5.7)
Bacteroides caccae 2 (2.9)
Bacteroides vulgatus 2 (2.9)
Fusobacterium nucleatum 1 (1.4)
Prevotella buccae 1 (1.4)
Clostiridium spp.  9 (12.9)
Bifidobacterium sp. 1 (1.4)
Eubacterium lentum 1 (1.4)
Veillonella parvula 3 (4.3)
Parvimonas micra 4 (5.7)
Total 70 (100.0)
Table 3. Antimicrobial activities against 44 Bacteroides fragilis group isolates in 2012
Antimicrobial agents
Bacteroides fragilis (32) B. fragilis group, other species (12)b
MIC (μg/mL)
% 
Susceptibilitya
MIC (μg/mL)
% 
Susceptibility a
Range 90% S R Range 90% S R
Piperacillin      2-＞256 128 75 13          128-＞256 ＞256 0 100
Piperacillin-tazobactam   0.25-128 2 97 3 0.03-256 128 75 17
Cefoxitin 8-128 16 91 9  4-64 32 25 8
Cefotetan 4-256 32 81 9   8-256 256 17 67
Imipenem 0.06-32 1 97 3 0.06-8 8 83 0
Meropenem 0.12-256 1 91 6 0.125-4 2 100 0
Clindamycin 0.03-256 256 50 50   2-256 256 17 67
Moxifloxacin 0.25-32 8 78 16 0.5-64 32 75 25
Chloramphenicol 4-8 8 100 0 4-8 8 100 0
Metronidazole 0.5-4 4 100 0 1-2 2 100 0
aS, susceptible; R, resistant.
bBacteroides thetaiotaomicron  (n=6), B. caccae  (n=2), B. ovatus  (n=2), B. vulgatus  (n=2).
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4. Therapy and outcome
During the study period, patients were hospitalized for (13.5 
[4, 36]) days (median, [first quartile ,third quartile], range 1-166 
days) and 15 patients (21.4%) died within 28 days of the onset 
of bacteremia. Fifty-one patients (72.9%) received appropriate 
antimicrobial therapy: piperacillin-tazobactam in 24 patients, 
carbapenem in 20 patients, and metronidazole in six patients. 
Sixteen patients received inappropriate therapy with either in-
effective antimicrobials or an inadequate time of initiation 
(Fig. 1A). Six of the 16 patients who received inappropriate 
therapy died, and 4 of these 6 patients underwent therapy that 
included third-generation cephalosporin and other agents 
known to be ineffective against AB. Five of the 6 patients were 
deemed to be expired due to bacteremia within 1 to 5 days af-
ter the blood culture were drawn. Among the ten live patients 
of the 16 patients who received inappropriate therapy, six pa-
tients were treated with third-generation cephalosporins and 
other agents known to be ineffective against AB, three patients 
did not receive any antimicrobial therapy, and one patient un-
derwent delayed therapy with carbapenem. The appropriate-
ness of therapy was not significant in mortality by univariate 
and multivariate analysis, however, survival rate of bacteremia 
was significantly worse in patients who received inappropriate 
therapy compared with those underwent appropriate therapy 
by Cox proportional-hazards regression analysis (hazard ratio, 
5.4; 95% confidence interval, 1.7–16.9; P = 0.004) (Fig. 1B).
Figure 1. Clinical outcome and survival rate of 70 patients with anaerobic bacteremia according to appropriateness of 
treatment(A, B).
A
B
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Discussion 
Clinical decision making is more difficult in anaerobic infec-
tions than aerobic infections, because of its limitations in iso-
lating and susceptibility testing, such as slow growth of organ-
isms, complexity of  testing method and predictable 
susceptibility patterns among the anaerobes [14]. However, 
AB has reemerged as a signiﬁcant clinical problem, owing to 
multiple reasons, such as change of medical practices and in-
creasing number of patients with complex underlying diseas-
es [15]. Similarly, from the trends in AB that we have followed 
since 1974, the incidence of AB has gradually increased in the 
last four decades, from 1.39% in 1974-1983 to 1.96% in 2007-
2008 [16-18]. There were technological advances in blood cul-
ture detection systems in our institution, blood culture sys-
tems from conventional anaerobic broth blood systems to 
BACTEC 9240 systems (Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MA, USA) in 1997 and to BacT/Alert 
3D systems (bioMérieux) in 2005, however, the steady rather 
than sudden increase was noted during the decades. Accord-
ing to an annual report from the Korean Ministry of Health 
and Welfare [19], the number of elderly patients and patients 
with underlying malignancies is increasing and we assume 
that the change in patient population attributed to this trend 
we observed. Indeed, patients admitted to the Severance Hos-
pital, a tertiary care referral center, often present with comor-
bidities and advanced disease. 
To our knowledge, this is the first study in Korea to demon-
strate a correlation between risk factors and mortality, using 
χ2 test and Cox proportional-hazards regression model for sta-
tistical analysis. In this study of AB, there were three findings: 
1) mortality of patients with AB is associated with cardiovas-
cular disease as an underlying disease; and 2) more than half 
of AB is derived from HA infection; and 3) the survival was 
significantly worse in patients who received inappropriate 
therapy compared with those underwent appropriate therapy.
The cardiovascular disease as an underlying condition was 
significantly associated with mortality, which is a novel find-
ing in this study. Yang et al. [20] reported this comorbidity as 
not being a significant risk factor for 30-day mortality, howev-
er, the limitation in scope to a single species such as Clostridi-
um perfringens, and different assessment of patient demo-
graphics may have contributed to discordant results. The 
relationship between cardiovascular disease and mortality in 
AB patients has not been demonstrated, so further investiga-
tion is needed.
The nosocomial acquisition of AB was commonly estimated 
in previous studies, from 25% to 64% of AB cases [20, 21]. The 
nosocomial bacteremia was defined as a positive blood cul-
ture obtained more than 48 h after admission in previous 
studies. However, due to a complexity in the delivery of 
healthcare services, the category and definition of blood 
stream infection has changed. Based on the proposed defini-
tion of CA, HA, and HCA infection, 62.9% of cases were HA in-
fection in this study. 
Inappropriate therapy has been regarded as a prognostic 
factor in patient outcomes [6, 22], and was also found to be 
statistically significant for the survival rate in this study. In the 
period of this study, 54 patients (77.1%) received initial thera-
py that was appropriately effective against AB, which is not 
much different from some studies that have reported values of 
72-80% [6]. Among six expired cases of 16 patients who un-
derwent inappropriate therapy, four patients had active can-
cer with multiple metastasis, one had acute pulmonary edema 
due to heart failure and one had traumatic subdural hemor-
rhage with coma metal status. Five of six patients had therapy 
using third-generation cephalosporin or colistin and one pa-
tient had no antimicrobials given. Generally, in our hospital, 
monotherapy of third-generation cephalosporin or piperacil-
lin-tazobactam is recommended as the intial therapy when 
systemic infection is suspected, and carbapenam or vancomy-
cin is considered in severe infections. AB is not empirically 
treated at the initial time of infection, but metronidazole is ad-
ministered in clinically suspicious circumstances or when pri-
or antimicrobial therapy has failed. 
Several factors have been suggested to have an association 
with a greater likelihood of inappropriate antimicrobial thera-
py, such as presence of multiple infecting organisms, antibiot-
ic-resistant bacteria, and prolonged length of stay [23]. In this 
study, however, there was no case of polymicrobial infection 
or use of antimicrobial agents that the isolate showed resis-
tance in the inappropriately treated groups, and length of hos-
pital stay was longer in the appropriately treated group com-
pared with the inappropriately treated group (30 vs. 17.6 
days). We assume that impression of patients with risk of AB is 
important in the clinical outcome as observed in our study 
that inappropriately treated groups showed worse survival. In 
addition, our findings regarding patient characteristics may 
guide physicians with clinical clues.
The limitations of the present study are that it was a restro-
spective review and was done with a small sample size. De-
spite these limitations, in conclusion, AB was frequently noted 
in patients having maliganancy and the mortality rate in pa-
tients with clinically significant AB was 21%. B. fragilis was the 
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most frequently recovered organism with predictable suscep-
tibility patterns. The survival rate of AB was significantly worse 
in patients who received inappropriate therapy compared 
with those underwent appropriate therapy and choice of 
proper initial antimicrobial is fundamental in clinical out-
come of AB.
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